ONE MAIN STREET, CAMBRIDGE, MA
Zipalertinib and Chemotherapy Achieve PFS Endpoint in REZILIENT3 Trial
Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Stockholders Elect Directors and Ratify KPMG as Auditor at Annual Meeting
Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases
Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress
To Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress
Provides Corporate Update and Reports First Quarter 2026 Financial Results
Annual Report to Security Holders
Q2
Q1
FY 2025
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Amended Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
Schedule 13G - Ownership Report
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload